{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:22:47Z","timestamp":1787062967482,"version":"build-2736575974"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003402","name":"Fundaci\u00f3n Valle del Lili","doi-asserted-by":"publisher","award":["2025-ART-001"],"award-info":[{"award-number":["2025-ART-001"]}],"id":[{"id":"10.13039\/501100003402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003402","name":"Fundaci\u00f3n Valle del Lili","doi-asserted-by":"publisher","award":["2025-ART-001"],"award-info":[{"award-number":["2025-ART-001"]}],"id":[{"id":"10.13039\/501100003402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mucopolysaccharidosis IVA (MPS IVA, Morquio A syndrome) is a rare lysosomal storage disorder caused by mutations in the GALNS gene, resulting in N-acetylgalactosamine-6-sulfatase (GALNS) deficiency and accumulation of keratan sulfate and chondroitin-6-sulfate. MPS IVA primarily affects the skeletal system, leading to progressive dysplasia and multi-organ involvement. Although enzyme replacement therapy (ERT) with elosulfase alfa is currently the only approved treatment, its clinical benefit on bone pathology is limited due to rapid clearance and poor penetration into avascular cartilage. Strategies to enhance enzyme stability and targeting, such as PEGylated hydrogels and extracellular vesicles, have shown promise in enhancing the biodistribution and stability of GALNS, while pharmacological chaperones, including ezetimibe, pranlukast, and bromocriptine, seem to stabilize GALNS in vitro. Promisingly, gene therapy (GT) has demonstrated significant preclinical progress using adeno-associated virus (AAV), lentiviral (LV), and CRISPR\/Cas9 platforms. For instance, AAV vectors employing bone-targeting peptides and tandem promoters improve skeletal manifestations in murine and rat models. Similarly, recent ex vivo LV-based GT studies have opened new avenues in the treatment of MPS IVA. Furthermore, CRISPR\/nCas9-based strategies targeting safe harbor loci have successfully restored GALNS activity in MPS IVA fibroblasts and mouse models supporting the notion that gene editing may represent a potential therapeutic approach. On the other hand, antisense-based therapies using modified U7 small nuclear RNAs and circular RNAs offer novel approaches to correct pseudoexon activation from deep-intronic variants while expanding the therapeutic alternatives in MPS IVA. Importantly, recent evidence revealed that mitochondrial dysfunction in chondrocytes may contribute to the pathology of MPS IVA, uncovering new targets beyond GALNS enzyme activity recovery. This review highlights recent advances in the treatment of MPS IVA and discusses new directions to improve outcomes in MPS IVA treatment.<\/jats:p>","DOI":"10.1186\/s13023-025-04028-0","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:36:07Z","timestamp":1760448967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recent advances in mucopolysaccharidosis IVA treatment"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-1986","authenticated-orcid":false,"given":"Andr\u00e9s Felipe","family":"Leal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2672-0439","authenticated-orcid":false,"given":"Harry","family":"Pachajoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"4028_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216148","author":"AF Leal","year":"2023","unstructured":"Leal AF, Alm\u00e9ciga-D\u00edaz CJ, Tomatsu S. Mucopolysaccharidosis IVA: current disease models and drawbacks. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms242216148.","journal-title":"Int J Mol Sci"},{"key":"4028_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041517","author":"K Sawamoto","year":"2020","unstructured":"Sawamoto K, et al. Mucopolysaccharidosis IVA: diagnosis, treatment, and management. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21041517.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4028_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108507","volume":"142","author":"E Rintz","year":"2024","unstructured":"Rintz E, et al. Causes of death in mucopolysaccharidoses. Mol Genet Metab. 2024;142(3):108507.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4028_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11020273","volume":"11","author":"B \u00c7elik","year":"2021","unstructured":"\u00c7elik B, et al. Epidemiology of mucopolysaccharidoses update. Diagnostics. 2021;11(2):273.","journal-title":"Diagnostics"},{"issue":"5","key":"4028_CR5","first-page":"475","volume":"63","author":"A Uribe-Ardila","year":"2022","unstructured":"Uribe-Ardila A, Ramirez-Borda J, Ayala A. Twenty years of Colombian experience with enzymatic screening in patients with features of mucopolysaccharidosis. JIMD Rep. 2022;63(5):475\u201383.","journal-title":"JIMD Rep"},{"key":"4028_CR6","doi-asserted-by":"crossref","unstructured":"G\u00f3mez AM, Su\u00e1rez-Obando G-RR. F, Estimation of the Mucopolysaccharidoses Frequencies and Cluster Analysis in the Colombian Provinces of Cundinamarca and Boyac\u00e1. 2012. 32, 602\u2013609.","DOI":"10.7705\/biomedica.v32i4.574"},{"issue":"1","key":"4028_CR7","doi-asserted-by":"publisher","DOI":"10.1590\/1678-4685-gmb-2020-0138","volume":"44","author":"JA Josahkian","year":"2021","unstructured":"Josahkian JA, et al. Updated birth prevalence and relative frequency of mucopolysaccharidoses across Brazilian regions. Genet Mol Biol. 2021;44(1):e20200138.","journal-title":"Genet Mol Biol"},{"issue":"6","key":"4028_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15060679","volume":"15","author":"A Tulebayeva","year":"2025","unstructured":"Tulebayeva A, et al. The birth prevalence of mucopolysaccharidosis types I, II, III, IVA, VI, and VII in the Republic of Kazakhstan between 1984 and 2023. Diagnostics. 2025;15(6):679.","journal-title":"Diagnostics"},{"issue":"3","key":"4028_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ajmg.c.31936","volume":"187","author":"H Pachajoa","year":"2021","unstructured":"Pachajoa H, et al. Molecular characterization of mucopolysaccharidosis type IVA patients in the Andean region of Colombia. Am J Med Genet C Semin Med Genet. 2021;187(3):388\u201395.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"4028_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s13023-021-01876-4","volume":"16","author":"B Stevens","year":"2021","unstructured":"Stevens B, et al. Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement. Orphanet J Rare Dis. 2021;16(1):394.","journal-title":"Orphanet J Rare Dis"},{"key":"4028_CR11","unstructured":"Lee CL, Chiu CC, Tu HC, Lo RY, Chang YT, Lin YH, Lin SP. HY., Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome. 2022, Drug Des Devel Ther. pp. 143\u2013154."},{"issue":"1","key":"4028_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13023-019-1074-9","volume":"14","author":"MU Akyol","year":"2019","unstructured":"Akyol MU, et al. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019;14(1):137.","journal-title":"Orphanet J Rare Dis"},{"key":"4028_CR13","doi-asserted-by":"crossref","unstructured":"Yalcin K, et al. Hematopoietic stem cell transplantation in children with mucopolysaccharidosis IVA: single center experience. Bone Marrow Transplant; 2024.","DOI":"10.21203\/rs.3.rs-4409630\/v1"},{"issue":"7","key":"4028_CR14","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","volume":"25","author":"M Taylor","year":"2019","unstructured":"Taylor M, et al. Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future. Biol Blood Marrow Transpl. 2019;25(7):e226\u201346.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4028_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.068","author":"S Kharbanda","year":"2025","unstructured":"Kharbanda S, et al. Allogeneic hematopoietic stem cell transplantation for patients with mucopolysaccharidosis IV a (Morquio A): an international retrospective study of 40 children. Transplant Cell Ther. 2025. https:\/\/doi.org\/10.1016\/j.jtct.2025.01.068.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"4028_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13052-025-01919-7","volume":"51","author":"W Zhang","year":"2025","unstructured":"Zhang W, et al. Allogeneic hematopoietic stem cell transplantation for mucopolysaccharidosis patients: a single-center experience and assessment of quality of life. Ital J Pediatr. 2025;51(1):83.","journal-title":"Ital J Pediatr"},{"issue":"7","key":"4028_CR17","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1021\/acsmedchemlett.0c00042","volume":"11","author":"S Olarte-Avellaneda","year":"2020","unstructured":"Olarte-Avellaneda S, et al. Bromocriptine as a novel pharmacological chaperone for mucopolysaccharidosis IV A. ACS Med Chem Lett. 2020;11(7):1377\u201385.","journal-title":"ACS Med Chem Lett"},{"issue":"13","key":"4028_CR18","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1021\/acs.jmedchem.9b00428","volume":"62","author":"CJ Alm\u00e9ciga-Diaz","year":"2019","unstructured":"Alm\u00e9ciga-Diaz CJ, et al. Identification of ezetimibe and pranlukast as pharmacological chaperones for the treatment of the rare disease mucopolysaccharidosis type IVA. J Med Chem. 2019;62(13):6175\u201389.","journal-title":"J Med Chem"},{"key":"4028_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30102222","author":"MG Davighi","year":"2025","unstructured":"Davighi MG, et al. Exploring Multivalent Architectures for Binding and Stabilization of N -Acetylgalactosamine 6-Sulfatase. Molecules. 2025. https:\/\/doi.org\/10.3390\/molecules30102222.","journal-title":"Molecules"},{"key":"4028_CR20","unstructured":"FNIH. The Foundation for the National Institutes of Health Announces Selection of Eight Rare Diseases for the Bespoke Gene Therapy Consortium Clinical Trial Portfolio. 2023 [cited 2023 August 8th]; Available from: https:\/\/fnih.org\/news\/the-foundation-for-the-national-institutes-of-health-announces-selection-of-eight-rare-diseases-for-the-bespoke-gene-therapy-consortium-clinical-trial-portfolio\/"},{"issue":"21\u201322","key":"4028_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1089\/hum.2024.094","volume":"35","author":"B Celik","year":"2024","unstructured":"Celik B, et al. Lentiviral vector-mediated ex vivo hematopoietic stem cell gene therapy for mucopolysaccharidosis IVA murine model. Hum Gene Ther. 2024;35(21\u201322):917\u201337.","journal-title":"Hum Gene Ther"},{"key":"4028_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26094334","author":"AM Herreno-Pach\u00f3n","year":"2025","unstructured":"Herreno-Pach\u00f3n AM, et al. CRISPR\/nCas9-Edited CD34\u2009+\u2009cells rescue mucopolysaccharidosis IVA fibroblasts phenotype. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26094334.","journal-title":"Int J Mol Sci"},{"key":"4028_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101153","author":"A Leal","year":"2023","unstructured":"Leal A, et al. Iron oxide-coupled CRISPR\/nCas9-based genome editing assessment in mucopolysaccharidosis IVA mice. Mol Ther Methods Clin Dev. 2023. https:\/\/doi.org\/10.1016\/j.omtm.2023.101153.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4028_CR24","first-page":"1","volume":"30","author":"AF Leal","year":"2022","unstructured":"Leal AF, Alm\u00e9ciga-D\u00edaz CJ. Alm\u00e9ciga-D\u00edaz, Efficient CRISPR\/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA. Gene Ther. 2022;30:1\u20138.","journal-title":"Gene Ther"},{"issue":"1","key":"4028_CR25","doi-asserted-by":"publisher","first-page":"15045","DOI":"10.1038\/s41598-022-19407-x","volume":"12","author":"AF Leal","year":"2022","unstructured":"Leal AF, et al. Delivery and assessment of a CRISPR\/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles. Sci Rep. 2022;12(1):15045.","journal-title":"Sci Rep"},{"issue":"11","key":"4028_CR26","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1517\/21678707.2015.1086640","volume":"3","author":"S Tomatsu","year":"2015","unstructured":"Tomatsu S, et al. Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations. Expert Opin Orphan Drugs. 2015;3(11):1279\u201390.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"6","key":"4028_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","volume":"37","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz CJ, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014;37(6):979\u201390.","journal-title":"J Inherit Metab Dis"},{"key":"4028_CR28","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-052648","author":"VC D\u00edaz Vidal","year":"2022","unstructured":"D\u00edaz Vidal VC, et al. Successful elosulfase alfa desensitization protocol in a patient with Morquio A syndrome. Pediatrics. 2022. https:\/\/doi.org\/10.1542\/peds.2021-052648.","journal-title":"Pediatrics"},{"issue":"4","key":"4028_CR29","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jaip.2017.02.020","volume":"5","author":"H Guvenir","year":"2017","unstructured":"Guvenir H, et al. Successful desensitization of elosulfase alfa-induced anaphylaxis in a pediatric patient with Morquio syndrome. J Allergy Clin Immunol Pract. 2017;5(4):1156\u20137.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"4028_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/pai.13049","volume":"30","author":"E Arroabarren","year":"2019","unstructured":"Arroabarren E, et al. Anaphylaxis after elosulfase A infusion: omalizumab as coadjuvant for enzyme replacement therapy desensitization. Pediatr Allergy Immunol. 2019;30(4):491\u20134.","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"4028_CR31","first-page":"104","volume":"58","author":"J Politei","year":"2021","unstructured":"Politei J, et al. Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes. JIMD Rep. 2021;58(1):104\u201313.","journal-title":"JIMD Rep"},{"issue":"7","key":"4028_CR32","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00276-019-02229-4","volume":"41","author":"M Baumgart","year":"2019","unstructured":"Baumgart M, et al. Quantitative anatomy of the primary ossification center in the fetal pubis bone. Surg Radiol Anat. 2019;41(7):755\u201361.","journal-title":"Surg Radiol Anat"},{"issue":"4","key":"4028_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s11914-011-0073-0","volume":"9","author":"CS Kovacs","year":"2011","unstructured":"Kovacs CS. Bone development in the fetus and neonate: role of the calciotropic hormones. Curr Osteoporos Rep. 2011;9(4):274\u201383.","journal-title":"Curr Osteoporos Rep"},{"key":"4028_CR34","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3389\/fimmu.2020.00588","volume":"11","author":"E Rackaityte","year":"2020","unstructured":"Rackaityte E, Halkias J. Mechanisms of fetal T cell tolerance and immune regulation. Front Immunol. 2020;11:588.","journal-title":"Front Immunol"},{"issue":"23","key":"4028_CR35","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1056\/NEJMoa2200587","volume":"387","author":"JL Cohen","year":"2022","unstructured":"Cohen JL, et al. Utero Enzyme-Replacement therapy for Infantile-Onset pompe\u2019s disease. N Engl J Med. 2022;387(23):2150\u20138.","journal-title":"N Engl J Med"},{"key":"4028_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.32132","author":"B Borges","year":"2025","unstructured":"Borges B, et al. Prenatal Delivery of Enzyme Replacement Therapy to Fetuses Affected by Early-Onset Lysosomal Storage Diseases. Am J Med Genet C Semin Med Genet. 2025;10.1002\/ajmg.c.32132.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"4028_CR37","doi-asserted-by":"publisher","first-page":"29329","DOI":"10.1038\/srep29329","volume":"6","author":"A Rodr\u00edguez-L\u00f3pez","year":"2016","unstructured":"Rodr\u00edguez-L\u00f3pez A, et al. Recombinant human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in the methylotrophic yeast Pichia pastoris. Sci Rep. 2016;6:29329.","journal-title":"Sci Rep"},{"key":"4028_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cryobiol.2021.12.004","volume":"105","author":"AM Alvarado-Fern\u00e1ndez","year":"2022","unstructured":"Alvarado-Fern\u00e1ndez AM, et al. Effect of two preservation methods on the viability and enzyme production of a recombinant Komagataella phaffii (Pichia pastoris) strain. Cryobiology. 2022;105:32\u201340.","journal-title":"Cryobiology"},{"issue":"12","key":"4028_CR39","doi-asserted-by":"publisher","first-page":"e32555","DOI":"10.1016\/j.heliyon.2024.e32555","volume":"10","author":"LN Pimentel-Vera","year":"2024","unstructured":"Pimentel-Vera LN, et al. Novel human Recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in a glyco-engineered. Heliyon. 2024;10(12):e32555.","journal-title":"Heliyon"},{"key":"4028_CR40","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.2147\/DDDT.S68562","volume":"9","author":"S Tomatsu","year":"2015","unstructured":"Tomatsu S, et al. Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome. Drug Des Devel Ther. 2015;9:1937\u201353.","journal-title":"Drug Des Devel Ther"},{"key":"4028_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/TACG.S69080","volume":"9","author":"DS Regier","year":"2016","unstructured":"Regier DS, Tanpaiboon P. Role of elosulfase alfa in mucopolysaccharidosis IVA. Appl Clin Genet. 2016;9:67\u201374.","journal-title":"Appl Clin Genet"},{"issue":"1","key":"4028_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ymgme.2007.01.004","volume":"91","author":"S Tomatsu","year":"2007","unstructured":"Tomatsu S, et al. Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase. Mol Genet Metab. 2007;91(1):69\u201378.","journal-title":"Mol Genet Metab"},{"key":"4028_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11100522","author":"JV \u00c1lvarez","year":"2019","unstructured":"\u00c1lvarez JV, et al. Enzyme-loaded gel core nanostructured lipid carriers to improve treatment of lysosomal storage diseases: formulation and in vitro cellular studies of elosulfase Alfa-loaded systems. Pharmaceutics. 2019. https:\/\/doi.org\/10.3390\/pharmaceutics11100522.","journal-title":"Pharmaceutics"},{"issue":"5","key":"4028_CR44","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s13346-020-00714-7","volume":"10","author":"E Jain","year":"2020","unstructured":"Jain E, et al. Biodegradable polyethylene glycol hydrogels for sustained release and enhanced stability of RhGALNS enzyme. Drug Deliv Transl Res. 2020;10(5):1341\u201352.","journal-title":"Drug Deliv Transl Res"},{"key":"4028_CR45","doi-asserted-by":"crossref","unstructured":"Flanagan M et al. Hydrogel Delivery Device for the In Vitro and In Vivo Sustained Release of Active rhGALNS Enzyme. Pharmaceuticals (Basel), 2023. 16(7).","DOI":"10.3390\/ph16070931"},{"key":"4028_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s12010-025-05266-5","author":"S Ruesing","year":"2025","unstructured":"Ruesing S, et al. RhGALNS enzyme stability in physiological buffers: implications for sustained release. Appl Biochem Biotechnol. 2025. https:\/\/doi.org\/10.1007\/s12010-025-05266-5.","journal-title":"Appl Biochem Biotechnol"},{"issue":"10","key":"4028_CR47","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.bbamcr.2018.07.001","volume":"1865","author":"AO Fedele","year":"2018","unstructured":"Fedele AO, et al. Lysosomal N-acetyltransferase interacts with ALIX and is detected in extracellular vesicles. Biochim Biophys Acta Mol Cell Res. 2018;1865(10):1451\u201364.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"5","key":"4028_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12058","volume":"10","author":"J Seras-Franzoso","year":"2021","unstructured":"Seras-Franzoso J, et al. Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders. J Extracell Vesicles. 2021;10(5):e12058.","journal-title":"J Extracell Vesicles"},{"issue":"11","key":"4028_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201801271","volume":"8","author":"MJ Haney","year":"2019","unstructured":"Haney MJ, et al. TPP1 delivery to lysosomes with extracellular vesicles and their enhanced brain distribution in the animal model of Batten disease. Adv Healthc Mater. 2019;8(11):e1801271.","journal-title":"Adv Healthc Mater"},{"issue":"8","key":"4028_CR50","doi-asserted-by":"publisher","first-page":"e42840","DOI":"10.1371\/journal.pone.0042840","volume":"7","author":"DM Iglesias","year":"2012","unstructured":"Iglesias DM, et al. Stem cell microvesicles transfer cystinosin to human cystinotic cells and reduce cystine accumulation in vitro. PLoS ONE. 2012;7(8):e42840.","journal-title":"PLoS ONE"},{"issue":"1","key":"4028_CR51","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13287-021-02355-0","volume":"12","author":"M Flanagan","year":"2021","unstructured":"Flanagan M, et al. Umbilical mesenchymal stem cell-derived extracellular vesicles as enzyme delivery vehicle to treat Morquio A fibroblasts. Stem Cell Res Ther. 2021;12(1):276.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"4028_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107648","volume":"140","author":"AF Leal","year":"2023","unstructured":"Leal AF, et al. Molecular trojan horses for treating lysosomal storage diseases. Mol Genet Metab. 2023;140(3):107648.","journal-title":"Mol Genet Metab"},{"key":"4028_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ph17060707","author":"Y Matsuzaka","year":"2024","unstructured":"Matsuzaka Y, Yashiro R. Current strategies and therapeutic applications of mesenchymal stem cell-based drug delivery. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17060707.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4028_CR54","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.2147\/IJN.S441467","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Mesenchymal stem Cell-Derived extracellular vesicles in Bone-Related diseases: intercellular communication messengers and therapeutic engineering protagonists. Int J Nanomed. 2024;19:3233\u201357.","journal-title":"Int J Nanomed"},{"key":"4028_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065819","author":"D Grasso","year":"2023","unstructured":"Grasso D, et al. Pharmacological chaperones and protein conformational diseases: approaches of computational structural biology. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24065819.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4028_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010232","volume":"21","author":"JC Losada D\u00edaz","year":"2019","unstructured":"Losada D\u00edaz JC, et al. Advances in the development of pharmacological chaperones for the mucopolysaccharidoses. Int J Mol Sci. 2019;21(1):232.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4028_CR57","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1016\/j.xphs.2019.03.034","volume":"108","author":"A Rodr\u00edguez-L\u00f3pez","year":"2019","unstructured":"Rodr\u00edguez-L\u00f3pez A, et al. Characterization of human recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Pichia pastoris as potential enzyme for mucopolysaccharidosis IVA treatment. J Pharm Sci. 2019;108(8):2534\u201341.","journal-title":"J Pharm Sci"},{"key":"4028_CR58","first-page":"50","volume":"18","author":"K Sawamoto","year":"2020","unstructured":"Sawamoto K, et al. Liver-targeted AAV8 gene therapy ameliorates skeletal and cardiovascular pathology in a mucopolysaccharidosis IVA murine model. Mol Ther. 2020;18:50\u201361.","journal-title":"Mol Ther"},{"issue":"23\u201324","key":"4028_CR59","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1089\/hum.2024.096","volume":"35","author":"AM Herre\u00f1o-Pach\u00f3n","year":"2024","unstructured":"Herre\u00f1o-Pach\u00f3n AM, et al. Adeno-associated virus gene transfer ameliorates progression of skeletal lesions in mucopolysaccharidosis IVA mice. Hum Gene Ther. 2024;35(23\u201324):955\u201368.","journal-title":"Hum Gene Ther"},{"key":"4028_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012693","author":"M Piechnik","year":"2022","unstructured":"Piechnik M, et al. Sex difference leads to differential gene expression patterns and therapeutic efficacy in mucopolysaccharidosis IVA murine model receiving AAV8 gene therapy. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232012693.","journal-title":"Int J Mol Sci"},{"key":"4028_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24129890","author":"E Rintz","year":"2023","unstructured":"Rintz E, et al. Bone growth induction in mucopolysaccharidosis IVA mouse. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24129890.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4028_CR62","doi-asserted-by":"publisher","first-page":"102211","DOI":"10.1016\/j.omtn.2024.102211","volume":"35","author":"E Rintz","year":"2024","unstructured":"Rintz E, et al. Molecular therapy and nucleic acid adeno-associated virus-based gene therapy delivering combinations of two growth-associated genes to MPS IVA mice. Mol Ther Nucleic Acids. 2024;35(2):102211.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"4028_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101447","volume":"33","author":"SA Khan","year":"2025","unstructured":"Khan SA, et al. Evaluation of AAV vectors with tissue-specific or ubiquitous promoters in a mouse model of mucopolysaccharidosis type IVA. Mol Ther Methods Clin Dev. 2025;33(2):101447.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"4028_CR64","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1038\/s41467-021-25697-y","volume":"12","author":"J Bertolin","year":"2021","unstructured":"Bertolin J, et al. Treatment of skeletal and non-skeletal alterations of mucopolysaccharidosis type IVA by AAV-mediated gene therapy. Nat Commun. 2021;12(1):5343.","journal-title":"Nat Commun"},{"issue":"12","key":"4028_CR65","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41434-021-00243-z","volume":"28","author":"JM Riyad","year":"2021","unstructured":"Riyad JM, Weber T. Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions. Gene Ther. 2021;28(12):683\u201396.","journal-title":"Gene Ther"},{"issue":"5","key":"4028_CR66","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.tim.2021.09.005","volume":"30","author":"NL Meyer","year":"2022","unstructured":"Meyer NL, Chapman MS. Adeno-associated virus (AAV) cell entry: structural insights. Trends Microbiol. 2022;30(5):432\u201351.","journal-title":"Trends Microbiol"},{"key":"4028_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.09.015","author":"A Pupo","year":"2022","unstructured":"Pupo A, et al. AAV vectors: the Rubik\u2019s cube of human gene therapy. Mol Ther. 2022. https:\/\/doi.org\/10.1016\/j.ymthe.2022.09.015.","journal-title":"Mol Ther"},{"key":"4028_CR68","doi-asserted-by":"publisher","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13:975803.","journal-title":"Front Immunol"},{"key":"4028_CR69","doi-asserted-by":"publisher","first-page":"82","DOI":"10.11144\/Javeriana.SC30.eotc","volume":"30","author":"DA Suarez","year":"2025","unstructured":"Suarez DA, Leal AF, Alm\u00e9ciga-D\u00edaz CJ. Alm\u00e9ciga-D\u00edaz, Evaluation of the CRISPR\/Cas9 system as genome editing platform for the Mucopolysaccharidosis IV A using a strategy for induction of higher homologous recombination frequency. Universitas Scientiarum. 2025;82\u2013106.","journal-title":"Universitas Scientiarum"},{"issue":"4","key":"4028_CR70","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41390-018-0095-8","volume":"84","author":"CJ Alm\u00e9ciga-D\u00edaz","year":"2018","unstructured":"Alm\u00e9ciga-D\u00edaz CJ, et al. Tailoring the AAV2 capsid vector for bone-targeting. Pediatr Res. 2018;84(4):545\u201351.","journal-title":"Pediatr Res"},{"issue":"30","key":"4028_CR71","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2201067119","volume":"119","author":"EL Schneider","year":"2022","unstructured":"Schneider EL, et al. A long-acting C-natriuretic peptide for achondroplasia. Proc Natl Acad Sci U S A. 2022;119(30):e2201067119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4028_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26104940","author":"Y Ago","year":"2025","unstructured":"Ago Y, et al. Identification of surrogate biomarkers for mucopolysaccharidosis type IVA. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26104940.","journal-title":"Int J Mol Sci"},{"key":"4028_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108708","volume":"262","author":"YA Dickinson","year":"2024","unstructured":"Dickinson YA, Moyes AJ, Hobbs AJ. C-type natriuretic peptide (CNP): the cardiovascular system and beyond. Pharmacol Ther. 2024;262:108708.","journal-title":"Pharmacol Ther"},{"issue":"7","key":"4028_CR74","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/biology11070986","volume":"11","author":"Y Nakagawa","year":"2022","unstructured":"Nakagawa Y, Nishikimi T. CNP, the Third Natriuretic Peptide: Its Biology and Significance to the Cardiovascular System. Biology. 2022;11(7):986.","journal-title":"Biology"},{"issue":"1","key":"4028_CR75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, et al. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):1\u201324.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4028_CR76","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41591-021-01554-9","volume":"28","author":"F Boulad","year":"2022","unstructured":"Boulad F, et al. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with \u03b2-thalassemia: a phase 1 trial. Nat Med. 2022;28(1):63\u201370.","journal-title":"Nat Med"},{"issue":"7","key":"4028_CR77","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone MC, O\u2019Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529\u201341.","journal-title":"Leukemia"},{"key":"4028_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24097736","author":"X Li","year":"2023","unstructured":"Li X, et al. Viral vector-based gene therapy. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24097736.","journal-title":"Int J Mol Sci"},{"key":"4028_CR79","doi-asserted-by":"publisher","first-page":"145527","DOI":"10.1016\/j.gene.2021.145527","volume":"780","author":"MA Puentes-Tellez","year":"2021","unstructured":"Puentes-Tellez MA, et al. Evaluation of HIV-1 derived lentiviral vectors as transductors of mucopolysaccharidosis type IV a fibroblasts. Gene. 2021;780:145527.","journal-title":"Gene"},{"key":"4028_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052456","author":"AF Leal","year":"2024","unstructured":"Leal AF, et al. Current strategies for increasing knock-in efficiency in CRISPR\/Cas9-based approaches. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25052456.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4028_CR81","doi-asserted-by":"publisher","first-page":"106968","DOI":"10.1016\/j.ymgme.2022.106968","volume":"138","author":"AF Leal","year":"2022","unstructured":"Leal AF, et al. The landscape of CRISPR\/Cas9 for inborn errors of metabolism. Mol Genet Metab. 2022;138(1):106968.","journal-title":"Mol Genet Metab"},{"key":"4028_CR82","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-0716-2301-5_6","volume":"2495","author":"J Gu","year":"2022","unstructured":"Gu J, et al. Targeting the AAVS1 site by CRISPR\/Cas9 with an inducible transgene cassette for the neuronal differentiation of human pluripotent stem cells. Methods Mol Biol. 2022;2495:99\u2013114.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"4028_CR83","doi-asserted-by":"publisher","first-page":"21474","DOI":"10.1038\/s41598-020-78450-8","volume":"10","author":"H Hayashi","year":"2020","unstructured":"Hayashi H, et al. Efficient viral delivery of Cas9 into human safe harbor. Sci Rep. 2020;10(1):21474.","journal-title":"Sci Rep"},{"issue":"6","key":"4028_CR84","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1021\/acssynbio.0c00097","volume":"9","author":"S Shin","year":"2020","unstructured":"Shin S, et al. Comprehensive analysis of genomic safe harbors as target sites for stable expression of the heterologous gene in HEK293 cells. ACS Synth Biol. 2020;9(6):1263\u20139.","journal-title":"ACS Synth Biol"},{"issue":"1","key":"4028_CR85","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1534\/g3.118.200758","volume":"9","author":"XA Ge","year":"2019","unstructured":"Ge XA, Hunter CP. Efficient homologous recombination in mice using long single stranded DNA and CRISPR Cas9 nickase. G3 Genes|Genomes|Genetics. 2019;9(1):281\u20136.","journal-title":"G3 Genes|Genomes|Genetics"},{"issue":"4","key":"4028_CR86","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nmeth.2857","volume":"11","author":"B Shen","year":"2014","unstructured":"Shen B, et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. 2014;11(4):399\u2013402.","journal-title":"Nat Methods"},{"issue":"2","key":"4028_CR87","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth CT, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249\u201354.","journal-title":"Nat Med"},{"issue":"2","key":"4028_CR88","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40262-021-01059-1","volume":"61","author":"ML Chan","year":"2022","unstructured":"Chan ML, et al. Pharmacokinetics and exposure-response of vosoritide in children with achondroplasia. Clin Pharmacokinet. 2022;61(2):263\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4028_CR89","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s12864-023-09645-2","volume":"24","author":"R Kurosawa","year":"2023","unstructured":"Kurosawa R, et al. PDIVAS: pathogenicity predictor for deep-intronic variants causing aberrant splicing. BMC Genomics. 2023;24(1):601.","journal-title":"BMC Genomics"},{"issue":"1","key":"4028_CR90","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s10020-025-01243-0","volume":"31","author":"I Bychkov","year":"2025","unstructured":"Bychkov I, Shchukina E, Zakharova E. Clinically relevant pseudoexons of the GALNS gene and their antisense-based correction. Mol Med. 2025;31(1):196.","journal-title":"Mol Med"},{"key":"4028_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108823","author":"AF Leal","year":"2025","unstructured":"Leal AF, Khan SA, Tomatsu S. Uncovering mitochondrial disturbances in MPS IVA chondrocytes. Mol Genet Metab. 2025. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108823.","journal-title":"Mol Genet Metab"},{"key":"4028_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010477","author":"AF Leal","year":"2022","unstructured":"Leal AF, et al. Mucopolysaccharidoses: cellular consequences of glycosaminoglycans accumulation and potential targets. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms24010477.","journal-title":"Int J Mol Sci"},{"key":"4028_CR93","doi-asserted-by":"publisher","first-page":"863667","DOI":"10.3389\/fphar.2022.863667","volume":"13","author":"AM Wiesinger","year":"2022","unstructured":"Wiesinger AM, et al. The inflammation in the cytopathology of patients with mucopolysaccharidoses- immunomodulatory drugs as an approach to therapy. Front Pharmacol. 2022;13:863667.","journal-title":"Front Pharmacol"},{"key":"4028_CR94","volume":"19","author":"H Fujitsuka","year":"2019","unstructured":"Fujitsuka H, et al. Biomarkers in patients with mucopolysaccharidosis type II and IV. Mol Genet Metab Rep. 2019;19:100455.","journal-title":"Mol Genet Metab Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04028-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04028-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04028-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:41:47Z","timestamp":1760456507000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04028-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4028"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04028-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"512"}}